Is UK evaluation of reproductive tech a model for US?
When the United Kingdom resoundingly approved mitochondrial replacement therapy in February, it became the first country to give people this new medical option. In parallel it gave the United States serious cause to reflect on how it handles matters of reproductive innovation, argues a trio of experts in the journal Science.
"We have fundamentally different regulatory cultures," said co-author Dr. Eli Adashi, former dean of medicine and biological sciences at Brown University.
The essay's other authors are I. Glenn Cohen of Harvard law and ethicist Julian Savulescu of the University of Oxford. [...]bioethics biotechnology fda genetics health law policy i. glenn cohen international regulation reproductive technologies